Aarti Pharmalabs Limited
Aarti Pharmalabs Limited (AARTIPHARM) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
aartipharmalabs.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 440 Cr | 449 Cr | 506 Cr | 555 Cr | 458 Cr | 538 Cr | 564 Cr | 386 Cr | 418 Cr | 432 Cr | 583 Cr | 536 Cr |
| Operating expenses (approx.) | 352 Cr | 353 Cr | 388 Cr | 459 Cr | 364 Cr | 409 Cr | 418 Cr | 291 Cr | 344 Cr | 330 Cr | 470 Cr | 400 Cr |
| EBITDA | 88 Cr | 96 Cr | 118 Cr | 96 Cr | 94 Cr | 129 Cr | 146 Cr | 95 Cr | 75 Cr | 102 Cr | 113 Cr | 136 Cr |
| OPM % | 20.0% | 21.3% | 23.2% | 17.4% | 20.5% | 23.9% | 25.8% | 24.7% | 17.9% | 23.7% | 19.4% | 25.4% |
| Other income | 0.98 Cr | 1 Cr | 2 Cr | 2 Cr | 4 Cr | 5 Cr | -2 Cr | 2 Cr | 0.05 Cr | -0.37 Cr | 8 Cr | 0.45 Cr |
| Interest | 4 Cr | 4 Cr | 5 Cr | 5 Cr | 6 Cr | 10 Cr | 7 Cr | 7 Cr | 11 Cr | 13 Cr | 17 Cr | 13 Cr |
| Depreciation | 18 Cr | 19 Cr | 19 Cr | 20 Cr | 21 Cr | 23 Cr | 23 Cr | 23 Cr | 25 Cr | 29 Cr | 28 Cr | 30 Cr |
| Profit before tax | 67 Cr | 74 Cr | 96 Cr | 74 Cr | 72 Cr | 101 Cr | 115 Cr | 65 Cr | 39 Cr | 63 Cr | 82 Cr | 101 Cr |
| Tax % | 22.6% | 28.5% | 31.9% | 24.7% | 23.9% | 26.5% | 22.9% | 24.4% | 27.8% | 23.7% | 25.2% | 24.7% |
| Net profit | 52 Cr | 53 Cr | 65 Cr | 55 Cr | 55 Cr | 74 Cr | 88 Cr | 50 Cr | 28 Cr | 48 Cr | 61 Cr | 76 Cr |
| EPS (₹) | ₹5.72 | ₹5.82 | ₹7.20 | ₹6.12 | ₹6.03 | ₹8.16 | ₹9.75 | ₹5.46 | ₹3.08 | ₹5.29 | ₹6.74 | ₹8.40 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 1,945 Cr | 1,853 Cr | 2,115 Cr | 1,819 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,603 Cr | 1,467 Cr | 1,651 Cr | 1,450 Cr | Sign in for TTM |
| EBITDA | 342 Cr | 386 Cr | 464 Cr | 369 Cr | Sign in for TTM |
| OPM % | 17.6% | 20.8% | 22.0% | 20.3% | Sign in for TTM |
| Other income | 2 Cr | 5 Cr | 10 Cr | 10 Cr | Sign in for TTM |
| Interest | 21 Cr | 17 Cr | 27 Cr | 47 Cr | Sign in for TTM |
| Depreciation | 63 Cr | 73 Cr | 87 Cr | 104 Cr | Sign in for TTM |
| Profit before tax | 261 Cr | 300 Cr | 361 Cr | 233 Cr | Sign in for TTM |
| Tax % | 25.8% | 27.8% | 24.5% | 25.0% | Sign in for TTM |
| Net profit | 193 Cr | 217 Cr | 272 Cr | 175 Cr | Sign in for TTM |
| EPS (₹) | ₹21.35 | ₹23.93 | ₹30.06 | ₹19.27 | Sign in for TTM |
| Dividend payout % | 0.0% | 8.4% | 11.6% | 20.8% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 45 Cr | 45 Cr | 45 Cr | 45 Cr |
| Reserves | 1,513 Cr | 1,712 Cr | 1,945 Cr | 2,079 Cr |
| Borrowings | 214 Cr | 264 Cr | 396 Cr | 686 Cr |
| Other liabilities | 458 Cr | 561 Cr | 520 Cr | 671 Cr |
| Total liabilities | 2,231 Cr | 2,582 Cr | 2,906 Cr | 3,482 Cr |
| Fixed assets (net) | 923 Cr | 1,015 Cr | 1,104 Cr | 1,336 Cr |
| CWIP | 62 Cr | 78 Cr | 307 Cr | 305 Cr |
| Investments | 74 Cr | 107 Cr | 77 Cr | 259 Cr |
| Loans & advances | 7 Cr | 1 Cr | 1 Cr | 0.50 Cr |
| Inventories | 602 Cr | 643 Cr | 588 Cr | 640 Cr |
| Trade receivables | 440 Cr | 519 Cr | 575 Cr | 583 Cr |
| Cash & bank | 25 Cr | 24 Cr | 7 Cr | 9 Cr |
| Other assets | 98 Cr | 195 Cr | 248 Cr | 349 Cr |
| Total assets | 2,231 Cr | 2,582 Cr | 2,906 Cr | 3,482 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operating activity | 263 Cr | 216 Cr | 332 Cr | 262 Cr |
| Cash from investing | -158 Cr | -215 Cr | -414 Cr | -431 Cr |
| Cash from financing | -163 Cr | 10 Cr | 65 Cr | 171 Cr |
| Net cash flow | -58 Cr | 12 Cr | -17 Cr | 2 Cr |
| Free cash flow (OCF − Capex) | 143 Cr | 18 Cr | -112 Cr | -186 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | 15.9% | 15.7% | 16.2% | 10.0% |
| ROE % | 12.4% | 12.3% | 13.7% | 8.1% |
| Debtor days | 82 | 102 | 99 | 117 |
| Inventory days | 216 | 273 | 241 | 281 |
| Days payable | 124 | 161 | 114 | 147 |
| Cash conversion cycle | 174 | 215 | 226 | 251 |
| Debt / equity | 0.14 | 0.15 | 0.20 | 0.32 |
| Current ratio | 1.95 | 1.94 | 2.01 | 1.49 |
| Net debt / EBITDA | 0.55 | 0.62 | 0.84 | 1.83 |
Compare with peers
Loading peers…